Expert Ratings For Waters

Across the recent three months, 6 analysts have shared their insights on Waters WAT, expressing a variety of opinions spanning from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $318.67, a high estimate of $358.00, and a low estimate of $275.00. Experiencing a 0.1% decline, the current average is now lower than the previous average price target of $319.00.

Breaking Down Analyst Ratings: A Detailed Examination

In examining recent analyst actions, we gain insights into how financial experts perceive Waters. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Waters. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Waters compared to the broader market.
• Price Targets: Analysts predict movements in price targets, offering estimates for Waters's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

To gain a panoramic view of Waters's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Waters analyst ratings.

Unveiling the Story Behind Waters

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.

Waters: Delving into Financials

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Negative Revenue Trend: Examining Waters's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -22.29% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Waters's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.05%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Waters's ROE excels beyond industry benchmarks, reaching 8.49%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Waters's ROA excels beyond industry benchmarks, reaching 2.24%. This signifies efficient management of assets and strong financial health.

Debt Management: Waters's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.64, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

Analyst Ratings: Simplified

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.